Management strategies for emergency surgery and major bleeding among DOAC users (N = 85)
| Scenario . | Strategy . | n (%) . |
|---|---|---|
| Management strategy for children on DOACs undergoing emergency surgery | Stop DOAC | 81 (95) |
| Four-factor prothrombin complex concentrate | 39 (46) | |
| (Fresh) frozen plasma | 26 (31) | |
| DOAC antidote | 19 (22) | |
| Recombinant factor VIIa | 14 (16) | |
| Activated prothrombin complex concentrate | 14 (16) | |
| Three-factor prothrombin complex concentrate | 11 (13) | |
| Other | 7 (8) | |
| Management strategy for DOAC reversal in children with major bleeding | Stop DOAC | 77 (91) |
| Four-factor prothrombin complex concentrate | 45 (53) | |
| (Fresh) frozen plasma | 37 (44) | |
| DOAC antidote | 27 (32) | |
| Recombinant factor VIIa | 29 (34) | |
| Activated prothrombin complex concentrate | 17 (20) | |
| Three-factor prothrombin complex concentrate | 12 (14) | |
| Other | 11 (13) |
| Scenario . | Strategy . | n (%) . |
|---|---|---|
| Management strategy for children on DOACs undergoing emergency surgery | Stop DOAC | 81 (95) |
| Four-factor prothrombin complex concentrate | 39 (46) | |
| (Fresh) frozen plasma | 26 (31) | |
| DOAC antidote | 19 (22) | |
| Recombinant factor VIIa | 14 (16) | |
| Activated prothrombin complex concentrate | 14 (16) | |
| Three-factor prothrombin complex concentrate | 11 (13) | |
| Other | 7 (8) | |
| Management strategy for DOAC reversal in children with major bleeding | Stop DOAC | 77 (91) |
| Four-factor prothrombin complex concentrate | 45 (53) | |
| (Fresh) frozen plasma | 37 (44) | |
| DOAC antidote | 27 (32) | |
| Recombinant factor VIIa | 29 (34) | |
| Activated prothrombin complex concentrate | 17 (20) | |
| Three-factor prothrombin complex concentrate | 12 (14) | |
| Other | 11 (13) |